Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Fractyl Health, Inc. Common Stock (GUTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: GUTS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.33
1 Year Target Price $9.33
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 6.75% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.42M USD | Price to earnings Ratio - | 1Y Target Price 9.33 |
Price to earnings Ratio - | 1Y Target Price 9.33 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 0.87 - 4.92 | Updated Date 07/8/2025 |
52 Weeks Range 0.87 - 4.92 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -161246.67% |
Management Effectiveness
Return on Assets (TTM) -49.05% | Return on Equity (TTM) -196.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 94741019 | Price to Sales(TTM) 1257.07 |
Enterprise Value 94741019 | Price to Sales(TTM) 1257.07 | ||
Enterprise Value to Revenue 1579.02 | Enterprise Value to EBITDA - | Shares Outstanding 48976600 | Shares Floating 18161026 |
Shares Outstanding 48976600 | Shares Floating 18161026 | ||
Percent Insiders 4.84 | Percent Institutions 82.44 |
Upturn AI SWOT
Fractyl Health, Inc. Common Stock
Company Overview
History and Background
Fractyl Health, Inc. is a metabolic therapeutics company focused on developing innovative treatments for type 2 diabetes (T2D) and other metabolic diseases. It was founded with the goal of addressing the root causes of these diseases rather than just managing symptoms.
Core Business Areas
- Revita DMR: Fractyl Health's primary focus is the Revita DMR (Duodenal Mucosal Resurfacing) system. This is a minimally invasive endoscopic procedure designed to remodel the duodenal lining in order to improve glycemic control in patients with T2D.
- Research and Development: Fractyl Health also engages in ongoing research and development to expand its understanding of metabolic diseases and develop new therapeutic approaches.
Leadership and Structure
Fractyl Health is led by a management team with expertise in medical devices, metabolic diseases, and commercialization. The organizational structure involves research and development, clinical operations, regulatory affairs, and commercial teams.
Top Products and Market Share
Key Offerings
- Revita DMR System: The Revita DMR System is Fractyl Health's primary product. It aims to treat the root causes of T2D by remodeling the duodenal lining to improve insulin sensitivity and glycemic control. Market share data is still developing, as it is a novel therapeutic and currently has not received FDA approval. Competitors include pharmaceutical companies offering T2D medications such as Novo Nordisk (NVO) and Eli Lilly (LLY) and other medical device companies exploring similar innovative therapies.
Market Dynamics
Industry Overview
The metabolic disease treatment market is large and growing, driven by the increasing prevalence of obesity and T2D. There is a significant unmet need for more effective therapies that address the underlying causes of these diseases.
Positioning
Fractyl Health aims to disrupt the T2D treatment landscape by offering a non-pharmacological approach that targets the duodenum. This could provide a unique competitive advantage if proven effective and safe.
Total Addressable Market (TAM)
The total addressable market for T2D treatments is estimated to be over $50 billion annually. Fractyl Health aims to capture a portion of this market by offering a potentially more effective and durable treatment option. The actual penetration would depend on clinical outcomes, regulatory approvals, and reimbursement.
Upturn SWOT Analysis
Strengths
- Novel technology addressing root cause of T2D
- Minimally invasive procedure
- Potential for durable glycemic control
- Strong intellectual property position
Weaknesses
- Limited clinical data compared to established therapies
- Dependence on regulatory approvals
- Reimbursement uncertainty
- Commercialization challenges for a new procedure
Opportunities
- Expansion into other metabolic diseases
- Partnerships with leading diabetes centers
- Publication of positive clinical trial results
- Increased awareness of the duodenum's role in T2D
Threats
- Regulatory setbacks
- Competition from established diabetes medications
- Negative clinical trial results
- Slow adoption by physicians and patients
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Medtronic (MDT)
- Johnson & Johnson (JNJ)
Competitive Landscape
Fractyl Health aims to differentiate itself by offering a non-pharmacological treatment option. Its competitive advantages lie in its innovative technology and potential for durable glycemic control. Disadvantages include regulatory hurdles and commercialization challenges.
Growth Trajectory and Initiatives
Historical Growth: Fractyl Health's historical growth has been focused on clinical development and regulatory milestones.
Future Projections: Future growth projections depend on FDA approval and the commercial success of Revita DMR. Analyst estimates are not yet widely available due to the company's early stage.
Recent Initiatives: Recent initiatives include advancing clinical trials, engaging with regulatory agencies, and building commercial infrastructure.
Summary
Fractyl Health is a development-stage company with a novel technology targeting the root cause of type 2 diabetes. Its success depends on clinical trial outcomes, regulatory approvals, and successful commercialization. While the technology shows promise, the company faces significant risks associated with clinical development and market adoption. Investing in Fractyl Health is high-risk and high-reward.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investing in development-stage companies involves significant risks, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fractyl Health, Inc. Common Stock
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2024-02-02 | Co-Founder, CEO & Director Dr. Harith Rajagopalan M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 109 | Website https://fractyl.com |
Full time employees 109 | Website https://fractyl.com | ||
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.